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OBJECTIVES: To compare observational data with a
large clinical study (MUCOSA) which showed that miso-
prostol reduced NSAID complication rates by 40% in pa-
tients with arthritis. To measure the cost of prescribing,
endoscopy and hospitalizations for patients receiving non-
steroidal anti-inflammatory drugs (NSAIDs) and estimate
the cost-effectiveness of misoprostol in routine practice.
METHODS: A cohort study using all patients in the Tay-
side region that received NSAIDs and anti-ulcer drugs be-
tween 1989 and 1995. Thirty-day treatment was esti-
mated from the cost of the NSAID plus endoscopies plus
hospitalization for GI events. Costs of hospitalizations
and endoscopic procedures were obtained from Scottish
Information and Statistics Division for 1997.
RESULTS: Among 54,807 eligible patients the risk ad-
justed rates of hospitalization for gastrointestinal diag-
noses were 50% lower on Arthrotec (a fixed combination
of misoprostol and diclofenac) than on diclofenac alone.
Statistically significant risk factors were: a prior history
of gastrointestinal events (p  0.001), a prior history of
cardiovascular events (p  0.001), increasing age (p 
0.001), social deprivation score (p  0.072), concurrent
exposure to anti-ulcer drugs (p  0.001) or steroids (p 
0.001) and type and dose of NSAID (p  0.001 and p 
0.047 respectively). Only nabumatone had a lower event
rate than Arthrotec, but at a higher expected cost. Ar-
throtec had lower 30 day treatment and complication
costs than diclofenac alone in high risk patients (e.g., £52
vs £86 for a patient aged 80–89 with a prior history of
GI events) but not in low risk patients (e.g., £16.50 vs
£15 for a patient aged 50–59 with no prior GI events).
CONCLUSIONS: There was close agreement between
this observational study and the MUCOSA study on the
extent to which the prophylactic use of misoprostol re-
duced NSAID associated gastrointestinal complications.
The combination of misoprostol with diclofenac should
reduce thirty day treatment and complication costs in
high risk patients, in comparison with diclofenac alone.
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OBJECTIVES: To investigate the cost-effectiveness of
high dose IV omeprazole as an adjuvant therapy to endo-
scopic hemostasis for prevention of early ulcer rebleeding
from a hospital perspective. A randomized, placebo-con-
trolled clinical trial was conducted previously in a local
hospital to study the effects of high dose IV omeprazole in-
fusion on patient outcomes after endoscopic ulcer hemo-
stasis. Although the interim data suggested that IV ome-
prazole significantly decreased the rate of early rebleeding
that occurred 72 hours after therapy, the cost implication
of this therapy has not been examined.
METHODS: The data of 157 patients who completed the
above study was analyzed. The percentages of patients who
experienced early rebleeding were obtained from medical
records. The health care resources consumed by each pa-
tient during the first 72 hours post endoscopic hemostasis
were also retrieved from their records and studied.
RESULTS: Four of 80 (5%) patients in the omeprazole
group and 17 of 77 (22%) patients from the placebo
group had rebleeding within 72 hrs after endoscopy and
required further treatment. The treatment cost within 72
hours post endoscopy of the IV omeprazole group was
lower than that of the placebo group (HK$1312 per pa-
tient vs. $3223 per patient, 1 US  7.8 HK). The cost-
effectiveness ratios for the omeprazole group and placebo
group were $9,946 and $12,821, respectively, per early re-
bleeding episode prevented.
CONCLUSIONS: High dose omeprazole is more cost-
effective in preventing early ulcer rebleeding than placebo
after endoscopic hemostasis.
GI3
EVALUATION OF PHARMACISTS’ 
INTERVENTIONS ON PRESCRIBING ERRORS 
OF NONSTEROIDAL ANTI-INFLAMMATORY 
DRUGS: COSTS SAVINGS AND 
CLINICAL EFFECTS
Cousin C, Misrahi L, Chamba G, Bauguil G, Colin C
Faculty of Pharmacy, Biological and Pharmaceutical Science 
Institute, Lyon, France
OBJECTIVES: To determine the economical and clinical
impact of pharmacists’ interventions in ambulatory care
within the context of a prescribing error of Nonsteroidal
Anti-Inflammatory Drugs (NSAIDs).
METHOD: A national survey was carried out in 900
town pharmacies during 12 weeks to record all prescrip-
tions with an anomaly like contraindication, interaction
which could be dangerous for the patient. We used a deci-
sion analysis to compare two strategies, with or without a
systematic pharmacist’s intervention before a prescription
of NSAIDs. The outcome was upper gastrointestinal side
effects of NSAID therapy (peptic ulcer and complications)
and we used a prescribing errors rate varying between
0,5% to 2% to estimate the costs savings and to measure
the occurrence of peptic ulcer avoided. Computer simula-
tion was performed with Tree Age 3.0.
RESULTS: 446 cases of NSAIDs prescription errors were
notified including combination of NSAIDs, NSAIDs over-
dose and NSAIDs prescription with risk factors like peptic
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ulcer history or age 65. Study gave an estimation of
49.390 prescriptions involving NSAIDs prescription at
risk of upper gastrointestinal side effects in France for one
year. The pharmacist’s intervention before a NSAID pre-
scription with an error lead to save 1.037.190 FF (158.119
Euros) to 3.951.200 FF (602.356 Euros) per year for the
Social Security and lead to avoid 58 to 232 peptic ulcers
per year (30 to 120 complicated ulcers).
CONCLUSION: This study confirmed that pharmacist in-
tervention is cost saving and has a clinical impact as regard
prescribing errors. Moreover this effect may be larger as
long as we only took into account the upper gastrointesti-
nal NSAIDs side effects.
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OBJECTIVES: To investigate the predictors of sample in-
clusion following the application of continuous eligibility
requirements for subjects receiving colonoscopies.
METHODS: All subjects with a colonoscopy (CPT 
45355–45385) in PharMetrics’ Integrated Outcomes Data-
base between January 1, 1997 and June 30, 1997; who did
not have a prior colonoscopy were eligible for the study.
For each subject, the date of his or her first colonoscopy
during the study period was identified. Subjects were then
classified as In-Sample if they had data available for analy-
sis 6 months prior to and following the index colonoscopy
date. Conversely, subjects without data available for analy-
sis 6 months prior to and following the index date were
considered Out-of-Sample. Subjects tumor types were clas-
sified as benign (ICD-9-CM  211.3, 211.4,569.0), malig-
nant (ICD-9-CM  154,153) or no-polyps (absence of any
of the tumor codes). Chronic comorbidities and gas-
trointestinal complications were identified via the presence
of ICD-9-CM codes. For each subject, the number of
chronic conditions identified during the study period was
counted. To determine the effect of subject characteristics
on sample inclusion, sample membership was modeled us-
ing logistic regression.
RESULTS: 6958 subjects met the inclusion criteria, of
which 58.28% were classified as In-Sample. Increasing age,
female gender and increasing number of comorbidities
were significantly associated with a greater likelihood of
sample inclusion. Benign tumors increased the likelihood of
sample inclusion (OR  1.17; 95% CI: 1.04–1.32), but
malignant tumors were not significantly associated with
sample inclusion (OR  1.14; 95% CI: 0.95–1.39).
CONCLUSIONS: Continuous eligibility requirements
tend to favor the inclusion of older subjects, subjects with
more comorbid conditions, and females. Subjects with be-
nign tumors, but not malignant tumors, are more likely to
remain in sample than those with no-polyps following the
application of continuous eligibility requirements.
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OBJECTIVES: To estimate the relative value attached to
several main characteristics associated with the process of
maternity care during the intrapartum stage for women
who have chosen to deliver at home compared with
women who have chosen to deliver in hospital.
METHODS: The attributes included in the exercise were
continuity of care, the location for delivery, the level of
pain relief available, the locus of control for decision-mak-
ing and the probability of being transferred to another lo-
cation during labor. The attributes and their associated
levels were chosen as a consequence of a literature review
and several focus groups held with women who had re-
cently delivered either at home or in hospital. A self-com-
pletion questionnaire using the conjoint analysis technique
was developed and administered to two samples. The first
sample comprised 250 women who had delivered in hospi-
tal within the preceding 12 months and who were clini-
cally defined as low risk prior to their delivery. The second
sample comprised 180 women who had delivered at home
within the preceding 12 months.
RESULTS: Response rates of 52% and 63% were achieved
for the hospital and home birth groups respectively. For the
hospital birth group, statistically significant attributes af-
fecting preferences were the level of continuity of care expe-
rienced (p  0.001) and the likelihood of transfer during
labor (p  0.012), with higher continuity of care and a
lower likelihood of transfer being preferred. For the home
birth group, statistically significant attributes included loca-
tion of care (p  0.001), pain relief (p  0.033) and the
likelihood of transfer during labor (p  0.028) with a
home location, more natural methods of pain relief and a
lower likelihood of transfer being preferred.
CONCLUSIONS: If, as suggested by recent evidence, it is
the case that there are no differences in the clinical out-
comes between home and hospital birth for low risk
women, then traditional measures used in health econom-
ics (e.g., quality adjusted life years or QALYs) would de-
tect no difference between the alternative modes of deliv-
ery. However, the results of this study suggests that aspects
associated with the process of maternity care are also im-
portant and these preferences differ considerably for
